Incidence of fungal infections in patients with hematologic cancer after the introduction of triazole prophylaxis.
| . | . | Aspergillus . | Candida . | |
|---|---|---|---|---|
| Disease . | Incidence . | . | After Triazoles . | Before Triazoles . |
| Abbreviations: AlloBMT, allogeneic bone marrow transplantation; Auto, autologous; PBSCT, peripheral blood stem cell transplant. | ||||
| Modified with permission from Thomson Current Drugs and Tahsine Mahfouz and Elias Anaissie, Prevention of fungal infections in the immunocompromised host. Current Opinion in Investigational Drugs. 2003 ;4 (8):974 –990.12 | ||||
| AlloBMT, PBSCT | 15–25% | 10–20% | < 5% | 15–25% |
| Acute myelogenous leukemia | 10–15% | 10% | < 5% | 15–20% |
| Acute lymphocytic leukemia | 5–10% | ~ 5% | < 5% | 10% |
| Auto-BMT, PBSCT | 2–6% | ≤ 2% | < 5% | 10% |
| . | . | Aspergillus . | Candida . | |
|---|---|---|---|---|
| Disease . | Incidence . | . | After Triazoles . | Before Triazoles . |
| Abbreviations: AlloBMT, allogeneic bone marrow transplantation; Auto, autologous; PBSCT, peripheral blood stem cell transplant. | ||||
| Modified with permission from Thomson Current Drugs and Tahsine Mahfouz and Elias Anaissie, Prevention of fungal infections in the immunocompromised host. Current Opinion in Investigational Drugs. 2003 ;4 (8):974 –990.12 | ||||
| AlloBMT, PBSCT | 15–25% | 10–20% | < 5% | 15–25% |
| Acute myelogenous leukemia | 10–15% | 10% | < 5% | 15–20% |
| Acute lymphocytic leukemia | 5–10% | ~ 5% | < 5% | 10% |
| Auto-BMT, PBSCT | 2–6% | ≤ 2% | < 5% | 10% |